Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

Breast Cancer Research and Treatment

Volumn 122, Issue 1, 2010, Pages 169-176

  Alba, Emilio ^a   Ruiz Borrego, Manuel ^b   Margelí, Mireia ^c   Rodríguez Lescure, Álvaro ^d   Sánchez Rovira, Pedro ^e   Ruiz, Amparo ^f   Mel Lorenzo, Jose Ramón ^e   Ramos Vázquez, Manuel ^g   Ribelles, Nuria ^a   Calvo, Elisa ^b   Casado, Antonio ^h   Márquez, Antonia ^a   Vicente, David ^b   García Sáenz, José Angel ^h   Martín, Miguel ^h  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^e Complejo Hospitalario de Jaén ^*  (Spain)

^f INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^g Centro Oncologico de Galicia   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Breast cancer advanced metastatic; Induction chemotherapy; Maintenance therapy; Pegylated liposomal doxorubicin

Indexed keywords

DOCETAXEL; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MACROGOL; TUBULIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; LIPOSOME; MACROGOL DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WATCHFUL WAITING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CARDIOMYOPATHY; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; FEMALE; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PARESTHESIA; PATHOLOGY;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CARDIOMYOPATHIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LIPOSOMES; MIDDLE AGED; MUCOSITIS; NEOPLASM METASTASIS; NEUTROPENIA; PARESTHESIA; POLYETHYLENE GLYCOLS; KAPLAN-MEIER ESTIMATE;

EID: 77953539402     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0860-9     Document Type: Article

References (20)

1. HT Mouridsen 1992 Systemic therapy of advanced breast cancer Drugs 44 Suppl 4 17 28 10.2165/00003495-199200444-00003 1283847
2. AS Coates M Byrne JF Bishop, et al. 1987 Improving the quality of life during chemotherapy for advanced breast cancer. Intermittent versus continuous chemotherapy for breast cancer N Engl J Med 317 1490 1495 1:STN:280: DyaL1c%2FmsFOntg%3D%3D 3683485
3. AL Harris BM Cantwell J Carmichael, et al. 1990 Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer Lancet 335 186 190 10.1016/0140-6736(90)90277-C 1:STN:280:DyaK3c7jsFKgtA%3D%3D 1967666 (Pubitemid 20054578)
4. HB Muss LD Case F Richards II, et al. 1991 Interrupted versus continuous chemotherapy in patients with metastatic breast cancer: the Piedmont Oncology Association N Engl J Med 325 1342 1348 1:STN:280:DyaK38%2FhvVSksg%3D%3D 1922236
5. B Ejlertsen P Pfeiffer D Pedersen, et al. 1993 Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months Eur J Cancer 29A 527 531 10.1016/S0959-8049(05)80145-5 1:STN:280:DyaK3s7mvVCntg%3D%3D 8435205
6. RK Gregory TJ Powles JC Chang, et al. 1997 A randomized trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast Eur J Cancer 33 2194 2197 10.1016/S0959-8049(97)00396-1 1:STN:280: DyaK1c7jtFGrsw%3D%3D 9470805 (Pubitemid 28123409)
7. G Falkson RS Gelman KJ Pandya, et al. 1998 Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment J Clin Oncol 16 1669 1676 1:CAS:528:DyaK1cXjtFOru7s%3D 9586877
8. French Epirubicin Study Group 2000 Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment J Clin Oncol 18 3115 3124
9. MA Nooij JCJM de Haes LVAM Beex, et al. 2003 Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: clinical outcomes and oncologists' preferences Eur J Cancer 39 614 621 10.1016/S0959-8049(02)00869-9 1:STN:280:DC%2BD3s7hsFCmuw%3D%3D 12628840 (Pubitemid 36287373)
10. A Gennari D Amadori M De Lena, et al. 2006 Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer J Clin Oncol 24 3912 3917 10.1200/JCO.2006.06.1812 1:CAS:528:DC%2BD28Xps1Sitrc%3D 16921042 (Pubitemid 46630739)
11. MR Stockler NJC Wilcken AS Coates 2003 Chemotherapy for advanced breast cancer: how long should it continue? Breast Cancer Res Treat 81 Suppl 1 S49 S52 10.1023/A:1026316806601 1:CAS:528:DC%2BD3sXosFajs78%3D
12. E Rivera 2003 Liposomal anthracyclines in metastatic breast cancer: clinical update Oncologist 8 Suppl 2 3 9 10.1634/theoncologist.8-suppl-2-3 1:CAS:528:DC%2BD3sXotF2qt7o%3D 13679590 (Pubitemid 37152051)
13. JA O'Shaughnessy 2003 Pegylated liposomal doxorubicin in the treatment of breast cancer Clin Breast Cancer 4 5 318 328 10.3816/CBC.2003.n.037 14715106
14. ®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 440 449 10.1093/annonc/mdh097 14998846 (Pubitemid 38444547)
15. 2 Ann Oncol 11 1029 1033 10.1023/A:1008365716693 1:STN:280:DC%2BD3cvoslOrsQ%3D%3D 11038041
16. Muggia F, Kim E, Gaiotti D, et al. (2004) Safety and response of prolonged Doxil therapy in recurrent gynecologic cancers. In: Program/proceedings of the 40th annual meeting of the American Society of Clinical Oncology, June 5-8, New Orleans, LA (abstract 5055)
17. D Uyar B Kulp G Peterson, et al. 2004 Cardiac safety profile of prolonged (≥6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies Gynecol Oncol 94 147 151 10.1016/j.ygyno.2004.03.024 1:CAS:528:DC%2BD2cXlslOqtrw%3D 15262133 (Pubitemid 38950511)
18. E Alba M Martín M Ramos, et al. 2004 Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) phase III study J Clin Oncol 22 2587 2593 10.1200/JCO.2004.08.125 1:CAS:528:DC%2BD2cXpsVWksL8%3D 15226326 (Pubitemid 41103745)
19. DJ Sargent DF Hayes 2008 Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol 26 1922 1923 10.1200/JCO.2007.14.8064 18421044
20. Beslija, et al. 2007 Second consensus on medical treatment of metastatic breast cancer Ann Oncol 18 2 215 225 10.1093/annonc/mdl155 1:STN:280: DC%2BD2s7ptFCkug%3D%3D 16831851 (Pubitemid 46323085)